Charles River Laboratories International, Inc. (CRL)
|Net Income (ttm)||396.08M|
|Day's Range||417.88 - 424.77|
|52-Week Range||219.79 - 460.21|
|Price Target||449.18 (+6.0%)|
|Est. Earnings Date||Nov 3, 2021|
Charles River Laboratories International, Inc., an early-stage contract research company, provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Support (Manufacturing). The RMS segment produces and sells research model strains and purpose-bred rats and mice for use by researchers. It also provides a range of services ... [Read more...]
In 2020, CRL's revenue was $2.92 billion, an increase of 11.55% compared to the previous year's $2.62 billion. Earnings were $364.30 million, an increase of 44.55%.Financial Statements
According to 14 analysts, the average rating for CRL stock is "Buy." The 12-month stock price forecast is 449.18, which is an increase of 5.98% from the latest price.
CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $CRL #LIFEatCRL--Charles River expands CRADL facilities in Cambridge, including growth of Binney Street site and the addition of a location on Bent Street.
Charles River's (CRL) recent partnership will enable the company to improve drug discovery projects by allowing structure-based design for a greater portfolio of targets.
Charles River and ATEM Structural Discovery Announce Strategic Partnership to Provide Clients with Cryo-EM Capabilities
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #HealthcareCollabReport--Charles River Laboratories International, Inc. (NYSE: CRL) and ATEM Structural Discovery (ATEM) today announced the formation of a st...
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #3Q2021--Charles River Laboratories schedules Third-Quarter 2021 earnings release and conference call
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL--Charles River Laboratories announces two divestitures.
Consecutive better-than-expected top- and bottom-line performances, and an encouraging 2021 guidance have been aiding Charles River (CRAI) stock.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #HealthcareCollabReport--The Healthcare Collaboration Report polled more than 1,500 Americans about the current state of healthcare, drug development, and pan...
Investors are optimistic about Charles River (CRL) on solid second-quarter performance and bullish 2021 guidance.
Business diversification and investor-friendly moves aid Charles River (CRAI) stock.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #CRL--Charles River Laboratories to participate in September Investor Conferences
Charles River (CRL) reported earnings 30 days ago. What's next for the stock?
Charles River (CRAI) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Charles River (CRAI) welcomes Randel R. Young to the position of senior consultantat its Energy Practice.
It's older than the dinosaurs.
Charles River (CRL) ended the second quarter on a strong note with solid performance by the RMS, DSA and Manufacturing Support arms driving the top line.
MODV vs. CRL: Which Stock Is the Better Value Option?
Charles River (CRAI) second-quarter 2021 earnings and revenues increase year over year.
Robust performance by all three segments drove Charles River's (CRL) revenues in the second quarter.
Charles River (CRL) delivered earnings and revenue surprises of 9.21% and 5.17%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Shares of Charles River (NYSE:CRL) were unchanged after the company reported Q2 results. Quarterly Results Earnings per share increased 65.19% year over year to $2.61, which beat the estimate of $2.38.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #2Q2021--Charles River Laboratories Announces Second-Quarter 2021 Results
Charles River's (CRL) biotech clients are likely to have benefited from a robust funding environment in Q2.
Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
WILMINGTON, Mass.--(BUSINESS WIRE)---- $CRL #2Q2021--Charles River Laboratories schedules second-quarter 2021 earnings release and conference call